Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
64 participants
INTERVENTIONAL
2024-10-22
2026-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Left Side BLT
Subjects will receive topical BLT applied to the left side of the face and 4% Lidocaine applied to the right side of the face prior to treatment.
Lidocaine topical
4%
BLT
Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Left Side Lidocaine
Subjects will receive topical 4% Lidocaine applied to the left side of the face and 4% BLT applied to the right side of the face prior to treatment.
Lidocaine topical
4%
BLT
Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine topical
4%
BLT
Topical Benzocaine 20%/ Lidocaine 8%/Tetracaine 4%
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who have a regularly scheduled dermatology appointment for Intense Pulse Light (IPL), Pulse Dye Laser (PDL), or microneedling.
Exclusion Criteria
* Patients with cardiac/respiratory disease, seizure disorder, or neuropathies.
* Patients who are under treatment for a dermatologic condition that may interfere with the evaluation of the study.
* Pregnant women and women who are breastfeeding.
* Patients who report concurrent use of anxiolytics or opiates, which may interfere with the interpretation of results.
18 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dartmouth-Hitchcock Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Brian.J.Simmons
Director of Clinical Trials
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian J Simmons, MD
Role: PRINCIPAL_INVESTIGATOR
Dartmouth Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dartmouth Hitchcock Dermatology Clinic
Lebanon, New Hampshire, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Nardin Awad, DO
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY02002464
Identifier Type: -
Identifier Source: org_study_id